News Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 07/03/2026 am IST			5-day change	1st Jan Change
95.94 ^USD	-1.43%		-5.26%	-2.87%

07/03	Incyte Receives European Commission Approval of Zynyz Regimen to Treat SCAC Anal Cancer	MT
07/03	Incyte - FDA issues complete response letter for Zynyz sbla in nsclc - SEC filing	RE

All News

07/03	Incyte Receives European Commission Approval of Zynyz Regimen to Treat SCAC Anal Cancer	MT
07/03	Incyte - FDA issues complete response letter for Zynyz sbla in nsclc - SEC filing	RE
07/03	Incyte announces the European Commission approval of Zynyz® (retifanlimab) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC)	RE
07/03	Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)	BU
07/03	Incyte Announces European Commission Approval of Zynyz (Retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal	CI
05/03	Evercore ISI Adjusts Price Target on Incyte to $110 From $73, Maintains In Line Rating	MT
02/03	Incyte Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 10:30 AM
02/03	Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata	AQ
28/02	Sector Update: Health Care Stocks Advance Late Afternoon	MT
27/02	Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata	CI
27/02	Eli Lilly, Incyte Get CHMP Backing for Olumiant in Adolescents With Severe Alopecia Areata	DJ
27/02	Eli Lilly, Incyte Say They Get EMA Panel's Positive Opinion for Olumiant to Treat Severe Alopecia Areata	MT
27/02	Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata	PR
26/02	Argus Adjusts Price Target on Incyte to $115 From $100, Maintains Buy Rating	MT
18/02	United Medical Ltda Announces Regulatory Submission of NIKTIMVO in Brazil	CI
18/02	Barclays Adjusts Price Target on Incyte to $117 From $116, Maintains Overweight Rating	MT
17/02	Incyte to Present at Upcoming Investor Conferences	BU
14/02	Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10)	RE
12/02	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
11/02	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
11/02	Deutsche Bank Adjusts Incyte Price Target to $98 From $70, Maintains Hold Rating	MT
11/02	Stifel Adjusts Price Target on Incyte to $120 From $119, Maintains Buy Rating	MT
11/02	TD Cowen Adjusts Price Target on Incyte to $123 From $128, Maintains Buy Rating	MT
11/02	Goldman Sachs Adjusts Price Target on Incyte to $98 From $90, Maintains Neutral Rating	MT
11/02	Morgan Stanley Raises Price Target on Incyte to $102 From $94, Keeps Equalweight Rating	MT